The global oncology based In-vivo CRO market size was valued at USD 2.19 billion in 2023 and is anticipated to reach around USD 4.99 billion by 2033, growing at a CAGR of 8.59% from 2024 to 2033.
The rising regularity with which big pharmaceutical companies outsource R&D activities, particularly in oncology, to focus on their core expertise is a significant market growth driver. Furthermore, the economic effectiveness of CROs, as opposed to completing an in-house study, would most certainly increase their demand during the predicted period.
Furthermore, the changing landscape of CROs and the rising need for diverse medications are projected to drive market expansion in the future years. In addition, biopharmaceutical and pharmaceutical investments in therapies drive R&D activities, as do drug development services. CROs have created their goods and services to assist manufacturers in getting traction with their R&D operations. Furthermore, economic instability is anticipated to boost outsourcing and contracting as biopharma and pharmaceutical companies address these problems. Small and medium-sized biopharmaceutical enterprises, in general, require more outsourcing due to limited resources.
Furthermore, due to their expertise and years of experience in the industry, CROs complete the assigned tasks at an extremely fast pace. According to a Tufts Center for the Study of Drug Development (CSDD) survey of top executives from major pharmaceutical companies, more than 75.0% believe CROs are more time-efficient than internal teams, boosting the demand for outsourcing.
Pharmaceutical companies are rapidly outsourcing R&D activities to CROs in order to remain competitive and agile in an era of expanding information, new technology, and volatile economic conditions. Companies prefer to outsource a wide range of activities from basic research to late-stage development, including target validation, hit exploration, lead optimization, genetic engineering, assay development safety, and efficacy tests in animal models as well as human clinical trials.
| Report Attribute |
Details |
| Market Size in 2024 | USD 2.38 Billion |
| Market Size by 2033 | USD 4.99 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 8.59% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Indication, region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Charles River Laboratory (CRL), ICON Plc, Thermo Fisher Scientific Inc., Eurofins Scientific, Taconic Biosciences, Crown Bioscience, Laboratory Corporation of America Holdings, WuXi AppTec, EVOTEC, The Jackson Laboratory |
U.S. Oncology Based In-vivo CRO Market Size, Industry Report, 2033
The U.S. oncology based In-vivo CRO market size was valued at USD xx billion in 2023 and is projected to surpass around USD xx billion by 2033, registering a CAGR of xx% over the forecast period of 2024 to 2033.
The North America oncology based in-vivo CRO market held the largest revenue share of 50.19% globally in 2023. This can be attributed to technologically advanced CROs in this region. The U.S. has the highest per capita healthcare spending, and the availability of funding and grants from government organizations such as the National Institute of Health (NIH) promotes research activities. The trend for reducing the R&D cost is most common in major life sciences companies. Clinical trial sponsors are under pressure due to the increasing complexity of the research methodology to reduce time and cost. The increasing R&D activities and the need to reduce the overall trial expenditure are expected to drive the need for CROs in North America.
U.S. Oncology Based In-vivo CRO Market Trends
The U.S. oncology based in-vivo CRO market accounted for the largest revenue share in the North American region in 2023 owing to rising funding, established market players, and a growing pipeline of oncology drugs. In addition, the country has many market players offering comprehensive in-vivo CRO services for various cancer types. This significant presence of CRO service providers and increasing collaboration among research institutes has significantly increased the demand for these in-vivo CROs across oncology. For instance, in July 2023, The University of Texas MD Anderson Cancer Center & Nexo Therapeutics announced a collaboration to utilize innovative technology & capabilities of each organization at the earliest stages of drug discovery & development to rapidly advance new cancer therapies against undruggable targets.
Europe Oncology Based In-vivo CRO Market Trends
The Oncology based in-vivo CRO market in Europe is expected to grow significantly due to presence of a large number of CROs,growing focus on R&D activities, and increasing trend of outsourcing to European countries. This is expected to contribute to the increasing demand for the market in this region.
The Germany oncology-based in vivo CRO market held the largest share in the European region in 2023, owing to the government initiative for clinical research activities and rising strategic partnerships among companies. Besides, advancements in technology and growing research activities in oncology are expected to propel this market over the forecast period.
The oncology-based in vivo CRO market in the UK is anticipated to grow over the forecast period owing to increased demand for CRO. To gain a larger market, further decreasing production costs by complying with the regulatory structure prevalent across the EU is expected to contribute to market growth.
Asia Pacific Oncology Based In-vivo CRO Market Trends
The oncology-based in vivo CRO market in Asia Pacific is expected to grow at a CAGR of 9.22% over the forecast period. The constant improvement in healthcare infrastructure, the presence of untapped opportunities, economic development, and a huge patient base are some factors responsible for the rapid growth. This region also ranks on top in ease of doing business. Moreover, with qualified labor and other resources available, Asia Pacific would be the key destination for in-vivo CRO projects over the forecast period.
The oncology based in vivo CRO market in China held the largest share in the Asia Pacific region in 2023 due to the growing focus on R&D of novel treatments, increasing pharmaceutical companies outsourcing, and higher cost efficiency provided by Chinese CROs.
The Japan oncology based in vivo CRO market is expected to grow over the forecast period due to the increasing demand for preclinical trials outsourcing and growing adoption of outsourcing models drive the market growth.
The oncology-based in vivo CRO market in India is anticipated to grow at the fastest CAGR over the forecast period, owing to the availability of established market players and rising oncology drug innovations. Besides, partnerships between pharma, biotech, and CROs drive the market.
The oncology based in vivo CRO market growth stage is medium, and its pace is accelerating. The market is characterized by the level of M&A activities, the degree of innovation, the impact of regulations, product expansions, and regional expansions.
The oncology-based in vivo CRO product categories have observed advancements due to the increasing frequency of outsourcing of R&D activities by various pharmaceutical companies. This further supports the development of the most efficient, relevant study design and screening method to identify various compounds and optimize lead candidates.
The growing presence of market players has made the market more competitive, leading to a rise in mergers and acquisitions. Besides, the market has been proven to facilitate gains, leadership retention, or international expansion.
Regulatory bodies and other authorities can influence the oncology-based in vivo CRO market. These regulations support the production of various oncology drugs using in vivo models.
Rising expansions, increasing R&D activities, and rising demand for various oncology-based drugs have led to a rise in demand for in-vivo CRO, further positively influencing the market dynamics.
The increase in R&D expenditure, the existence of technologically advanced service providers, and the rising requirement for oncology-based drugs have led the market growth.
The oncology-based in-vivo Contract Research Organization (CRO) market is witnessing significant growth and transformation. Several key trends are shaping this market, driven by the increasing complexity of cancer treatments and the demand for specialized research services.
Based on indication, the market is segmented into blood cancer, solid tumors, and others. In 2023, the solid tumor tests segment accounted for the largest revenue share of 47.89%. The segment is also anticipated to register the fastest CAGR growth over the forecast period. The factor responsible for higher research in solid tumors is the presence of over 800 new molecules in the research pipeline undertaken by large pharmaceutical companies. Furthermore, the availability of grants from institutes such as NIH and NCI, and the existing gap between the demand and supply of treatments for solid cancer also remain promising drivers of growth. Solid tumors are abnormal tissue mass that grows during cancer and affects various body parts, including organs, muscles, and bones. These are generally addressed as carcinomas and sarcomas.
The blood cancer segment is anticipated to grow at a CAGR of 8.76% over the forecast period. The rapid rise in investigational molecules for oncology and research in stem cells is anticipated to promote high investment within the in-vivo space for oncology. Blood cancer is inclusive of all the tumors that are either generated in the blood or have the capability to migrate within the blood system. Broadly, these comprise myelomas, lymphomas, and leukemia. This is expected to drive the market over the forecast period.
In November 2023, Crown Bioscience launched the OrganoidXploreTM service. It is an organoid panel screening platform service that offers robust, reproducible, and clinical output at record speed, propelling preclinical oncology drug discovery and reshaping the landscape of cancer treatment development.
In October 2023, Coeptis Therapeutics Holdings, Inc. announced research demonstrating the possibility of the SNAP-CAR T-cell platform to target numerous antigens. The research involved SNAP-CAR to demonstrate the technology's adaptable antigen-targeting abilities in vivo and in-vitro in xenograft models of human tumors.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Oncology Based In-vivo CRO market.
By Indication
By Region
Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Indication
1.3. Regional Scope
1.4. Estimates And Forecast Timeline
1.5. Objectives
1.5.1. Objective-1
1.5.2. Objective-2
1.5.3. Objective-3
1.6. Research Methodology
1.7. Information Procurement
1.7.1. Purchased Database
1.7.2. nova one advisors Internal Database
1.7.3. Secondary Sources
1.7.4. Primary Research
1.8. Information Or Data Analysis
1.8.1. Data Analysis Models
1.9. Market Formulation & Validation
1.10. Model Details
1.10.1. Commodity Flow Analysis
1.10.2. Parent Market Analysis
1.11. List Of Secondary Sources
1.12. List Of Abbreviations
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Oncology Based In-vivo CRO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Accelerating the time to market
3.2.1.2. Economic efficiency
3.2.1.3. Increasing mergers and collaborations
3.2.1.4. Increasing outsourcing of R&D Activities
3.2.2. Market Restraint Analysis
3.3. Oncology Based In-vivo CRO Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat Of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
3.3.4. Major Deals & Strategic Alliances Analysis
Chapter 4. Oncology Based In-vivo CRO Market: Indication Estimates & Trend Analysis
4.1. Oncology Based In-vivo CRO Market, By Indication: Segment Dashboard
4.2. Oncology Based In-vivo CRO Market, By Indication: Movement Analysis
4.3. Oncology Based In-vivo CRO Market Estimates & Forecasts, By Indication, 2018 - 2030
4.3.1. Blood cancer
4.3.1.1. Blood Cancer Market, 2021 to 2033 (USD Million)
4.3.1.2. Syngeneic model
4.3.1.2.1. Syngeneic model Market, 2021 to 2033 (USD Million)
4.3.1.3. Patient-derived xenograft
4.3.1.3.1. Patient derived xenograft Market, 2021 to 2033 (USD Million)
4.3.1.4. Xenograft
4.3.1.4.1. Xenograft Market, 2021 to 2033 (USD Million)
4.3.2. Solid tumor
4.3.2.1. Solid Tumor Market, 2021 to 2033 (USD Million)
4.3.2.2. Syngeneic model
4.3.2.2.1. Syngeneic model Market, 2021 to 2033 (USD Million)
4.3.2.3. Patient derived xenograft
4.3.2.3.1. Patient derived xenograft Market, 2021 to 2033 (USD Million)
4.3.2.4. Xenograft
4.3.2.4.1. Xenograft Market, 2021 to 2033 (USD Million)
4.3.3. Others
4.3.3.1. Others Market, 2021 to 2033 (USD Million)
4.3.3.2. Syngeneic model
4.3.3.2.1. Syngeneic model Market, 2021 to 2033 (USD Million)
4.3.3.3. Patient derived xenograft
4.3.3.3.1. Patient derived xenograft Market, 2021 to 2033 (USD Million)
4.3.3.4. Xenograft
4.3.3.4.1. Xenograft Market, 2021 to 2033 (USD Million)
Chapter 5. Oncology Based In-vivo CRO Market: Regional Estimates & Trend Analysis
5.1. Regional Market Share Analysis, 2024 & 2033
5.2. Regional Market Dashboard
5.3. Global Regional Market Snapshot
5.4. North America
5.4.1. Market Estimates and Forecast, 2021 - 2033 (Revenue, USD Million)
5.4.2. U.S.
5.4.2.1. Key Country Dynamics
5.4.2.2. Competitive Scenario
5.4.2.3. Regulatory Scenario
5.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
5.4.3. Canada
5.4.3.1. Key Country Dynamics
5.4.3.2. Competitive Scenario
5.4.3.3. Regulatory Scenario
5.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
5.4.4. Mexico
5.4.4.1. Key Country Dynamics
5.4.4.2. Competitive Scenario
5.4.4.3. Regulatory Scenario
5.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030
5.5. Europe
5.5.1. UK
5.5.1.1. Key Country Dynamics
5.5.1.2. Competitive Scenario
5.5.1.3. Regulatory Scenario
5.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
5.5.2. Germany
5.5.2.1. Key Country Dynamics
5.5.2.2. Competitive Scenario
5.5.2.3. Regulatory Scenario
5.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
5.5.3. France
5.5.3.1. Key Country Dynamics
5.5.3.2. Competitive Scenario
5.5.3.3. Regulatory Scenario
5.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
5.5.4. Italy
5.5.4.1. Key Country Dynamics
5.5.4.2. Competitive Scenario
5.5.4.3. Regulatory Scenario
5.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
5.5.5. Spain
5.5.5.1. Key Country Dynamics
5.5.5.2. Competitive Scenario
5.5.5.3. Regulatory Scenario
5.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
5.5.6. Denmark
5.5.6.1. Key Country Dynamics
5.5.6.2. Competitive Scenario
5.5.6.3. Regulatory Scenario
5.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
5.5.7. Sweden
5.5.7.1. Key Country Dynamics
5.5.7.2. Competitive Scenario
5.5.7.3. Regulatory Scenario
5.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
5.5.8. Norway
5.5.8.1. Key Country Dynamics
5.5.8.2. Competitive Scenario
5.5.8.3. Regulatory Scenario
5.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
5.6. Asia Pacific
5.6.1. Japan
5.6.1.1. Key Country Dynamics
5.6.1.2. Competitive Scenario
5.6.1.3. Regulatory Scenario
5.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
5.6.2. China
5.6.2.1. Key Country Dynamics
5.6.2.2. Competitive Scenario
5.6.2.3. Regulatory Scenario
5.6.2.4. China Market Estimates and Forecasts, 2018 - 2030
5.6.3. India
5.6.3.1. Key Country Dynamics
5.6.3.2. Competitive Scenario
5.6.3.3. Regulatory Scenario
5.6.3.4. India Market Estimates and Forecasts, 2018 - 2030
5.6.4. South Korea
5.6.4.1. Key Country Dynamics
5.6.4.2. Competitive Scenario
5.6.4.3. Regulatory Scenario
5.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
5.6.5. Australia
5.6.5.1. Key Country Dynamics
5.6.5.2. Competitive Scenario
5.6.5.3. Regulatory Scenario
5.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
5.6.6. Thailand
5.6.6.1. Key Country Dynamics
5.6.6.2. Competitive Scenario
5.6.6.3. Regulatory Scenario
5.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
5.7. Latin America
5.7.1. Brazil
5.7.1.1. Key Country Dynamics
5.7.1.2. Competitive Scenario
5.7.1.3. Regulatory Scenario
5.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
5.7.2. Argentina
5.7.2.1. Key Country Dynamics
5.7.2.2. Competitive Scenario
5.7.2.3. Regulatory Scenario
5.7.2.4. Argentina Market Estimates and Forecasts, 2018 - 2030
5.8. MEA
5.8.1. South Africa
5.8.1.1. Key Country Dynamics
5.8.1.2. Competitive Scenario
5.8.1.3. Regulatory Scenario
5.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
5.8.2. Saudi Arabia
5.8.2.1. Key Country Dynamics
5.8.2.2. Competitive Scenario
5.8.2.3. Regulatory Scenario
5.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
5.8.3. UAE
5.8.3.1. Key Country Dynamics
5.8.3.2. Competitive Scenario
5.8.3.3. Regulatory Scenario
5.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
5.8.4. Kuwait
5.8.4.1. Key Country Dynamics
5.8.4.2. Competitive Scenario
5.8.4.3. Regulatory Scenario
5.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030
Chapter 6. Competitive Landscape
6.1. Market Participant Categorization
6.1.1. Innovators
6.1.2. Market Leaders
6.1.3. Emerging Players
6.1.4. Company Market Share Analysis, 2023
6.2. Company Profiles
6.2.1. Charles River Laboratory (CRL)
6.2.1.1. Company Overview
6.2.1.2. Financial Performance
6.2.1.3. Service Benchmarking
6.2.1.4. Strategic Initiatives
6.2.2. ICON Plc
6.2.2.1. Company Overview
6.2.2.2. Financial Performance
6.2.2.3. Service Benchmarking
6.2.2.4. Strategic Initiatives
6.2.3. Thermo Fisher Scientific Inc.
6.2.3.1. Company Overview
6.2.3.2. Financial Performance
6.2.3.3. Service Benchmarking
6.2.3.4. Strategic Initiatives
6.2.4. Eurofins Scientific
6.2.4.1. Company Overview
6.2.4.2. Financial Performance
6.2.4.3. Service Benchmarking
6.2.4.4. Strategic Initiatives
6.2.5. Taconic Biosciences
6.2.5.1. Company Overview
6.2.5.2. Financial Performance
6.2.5.3. Service Benchmarking
6.2.5.4. Strategic Initiatives
6.2.6. Crown Bioscience
6.2.6.1. Company Overview
6.2.6.2. Financial Performance
6.2.6.3. Service Benchmarking
6.2.6.4. Strategic Initiatives
6.2.7. Lab Corp
6.2.7.1. Company Overview
6.2.7.2. Financial Performance
6.2.7.3. Service Benchmarking
6.2.7.4. Strategic Initiatives
6.2.8. WuXi AppTec
6.2.8.1. Company Overview
6.2.8.2. Financial Performance
6.2.8.3. Service Benchmarking
6.2.8.4. Strategic Initiatives
6.2.9. EVOTEC
6.2.9.1. Company Overview
6.2.9.2. Financial Performance
6.2.9.3. Service Benchmarking
6.2.9.4. Strategic Initiatives
6.2.10. The Jackson Laboratory
6.2.10.1. Company Overview
6.2.10.2. Financial Performance
6.2.10.3. Service Benchmarking
6.2.10.4. Strategic Initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers